Meta-chlorophenylpiperazine
 |
|
 |
|
| Clinical data | |
|---|---|
| Routes of administration |
Oral, Nasal, Rectal |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Biological half-life | 2-6 hours |
| Excretion | Renal |
| Identifiers | |
|
|
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| ECHA InfoCard | 100.026.959 |
| Chemical and physical data | |
| Formula | C10H13ClN2 |
| Molar mass | 196.676 g/mol |
| 3D model (Jmol) | |
|
|
|
|
  (what is this?)
|
|
meta-Chlorophenylpiperazine (mCPP) is a psychoactive drug of the phenylpiperazine class. It was initially developed in the late-1970s and used in scientific research before being sold as a designer drug in the mid-2000s. It has been detected in pills touted as legal alternatives to illicit stimulants in New Zealand and pills sold as "ecstasy" in Europe and the United States.
Despite its advertisement as a recreational substance, mCPP is actually generally considered to be an unpleasant experience and is not desired by drug users. It lacks any reinforcing effects, produces depressive and anxiogenic effects in rodents and humans, and can induce panic attacks in individuals susceptible to them. It also worsens obsessive-compulsive symptoms in people with the disorder.
mCPP is known to induce headaches in humans and has been used for testing potential antimigraine medications. It has potent anorectic effects and has encouraged the development of selective 5-HT2C receptor agonists for the treatment of obesity as well.
mCPP possesses significant affinity for the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, and 5-HT7 receptors, as well as the SERT. It also has some affinity for α1-adrenergic, α2-adrenergic, H1, I1, and NET. It behaves as an agonist at most or all serotonin receptors. mCPP has been shown to act not only as a reuptake inhibitor of serotonin but as a releasing agent as well.
...
Wikipedia